Ultra-widefield imaging provides visibility of the posterior segment in KPro patients

Article

Scanning laser ophthalmoscopy offers improved view of posterior segment.

Ultra-widefield imaging provides visibility of the posterior segment in KPro patients

Reviewed by William R. Bloom and Colleen M. Cebulla, MD, PhD.

The posterior segment is not readily visible in patients implanted with a Boston type I and II keratoprosthesis (KPro, Massachusetts Eye and Ear) when using standard fundus examination and photography.

However, ultra-widefield imaging scanning laser ophthalmoscopy seems to have remedied this and facilitates noninvasive monitoring of pathologies in the retina and optic nerve, according to William Bloom and Colleen Cebulla, MD, PhD, both of the Department of Ophthalmology and Visual Sciences at The Ohio State University Wexner Medical Center in Columbus.

Related: Combining SD-OCT and UWF improves macular pathology detection

The investigators conducted a retrospective chart review of 15 eyes of 14 patients who received either the Boston type I (n=14 eyes) or II (n=1 eye) KPro between 2009 and 2020 at the Wexner Medical Center.

The Optos ultra-widefield imaging system was used during 35 patient visits. A single masked reader graded image quality as poor, fair, good, or very good. The images were assessed for clinical pathologies of the retina and optic nerve.

Related: Adaptive optics SLO sheds light on fundus albipunctatus

Poor image was defined as one in which the structure of the optic disc or posterior segment was incomplete without meaningful clarity; fair image was defined as providing moderate structural resolution but not showing the complete posterior pole; good image was defined as providing a clear view of the entire posterior pole; and very good image was defined as excellent resolution with a field of view to the equatorial retina, Bloom explained.

Image quality

The image quality assessed was as follows: 1 of 35 images (2.9%) was considered poor and provided no visualization of posterior segment structures; 34 of 35 images (97.1%) were assessed as fair, good, or very good and provided at least some clinical utility.

Images that were clinically useful were obtained in the presence of both KPro models. Both the optic nerve and the macula were visible in 33 of 35 images (94.3%). Clinical pathologies in the study eyes included glaucoma, macular degeneration, and repaired retinal detachment. In 4 eyes, ultra-widefield images was performed serially at multiple visits (range, 3-9 individual visits), allowing for longitudinal follow-up (range, 3-46 months), Bloom said.

The investigators pointed out that images that were clinically useful were obtained despite poor visual acuity.

Related: Elucidating Alzheimer disease pathophysiology

“This ability allowed for longitudinal monitoring of insidious ocular clinical pathology, such as age-related macular degeneration and glaucoma,” the investigators wrote. “The ultra-widefield imaging provided clinically meaningful visualization of the optic nerve and anterior retina in most patients.”

The investigators also noted that in the presence of a retroprosthetic membrane the image quality was affected and it was difficult to image the anterior retina in all 4 quadrants simultaneously. However, implementing eye steering techniques, changing patient positions, and obtaining multiple images during an imaging session helped overcome these limitations.

Related: Ultra-widefield imaging can enhance efficiency for practices

Based on the results, ultra-widefield imaging was considered to be valuable because it can be performed rapidly and reliably to image the posterior segment compared with the standard technologies.

“Ultra-widefield imaging provides adequate visualization of the posterior segment in patients implanted with the KPro. Importantly, this imaging modality allowed noninvasive longitudinal monitoring of the retinal and optic nerve clinical pathology in this select patient population,” they concluded.

William R. Bloom
E: William.Bloom@osumc.edu
This article is adapted from Bloom’s presentation at the Association for Research in Vision and Ophthalmology 2021 annual meeting held virtually in May. He has no financial interest in this subject matter.
Colleen M. Cebulla, MD, PhD
E: colleen.cebulla@osumc.edu
Cebulla has no financial interest in this subject matter.

Related Content: Imaging | Diabetic Macular Edema | Ophthalmology

Related Videos
TENAYA, LUCERNE year 2 data reveals promising results for faricimab
How to diagnose geographic atrophy earlier
World Sight Day 2022: Eye care professionals share what global vision means to them
Samsara Vision update: Concerto trial recruiting patients with late-stage AMD
Understanding fluid dynamics in wet macular degeneration
YOSEMITE, RHINE treat-and-extend data show favorable results for faricimab for the treatment of DME
What are you most excited about in the field of retina? Tunde Peto, MD, PhD weighs in
Leveraging noninvasive ophthalmic imaging for patients with Alzheimer disease and analyzing UK Biobank data
EURETINA 2022: Leadership discusses what to expect, outlines Women in Retina program
DAVIO trial update: 12-month safety results indicate no serious adverse events, reduced treatment burden
© 2024 MJH Life Sciences

All rights reserved.